Epigenomics unlocks the potential of precision medicine
Explore the world of epigenomics and its impact on cancer research in conversation with Dr. Jorg Tost and Prof. Martin Hirst
16 Oct 2023
Industry news
New insights in epigenomics can shape the next generation of personalized medicine, including for immuno-oncology applications.
Dr. Jorg Tost, Head of the Laboratory for Epigenetics & Environment at CEA – IBFJ, and Prof. Martin Hirst, Professor and Director of Michael Smith Laboratories at The University of British Columbia, are driving efforts to advance human epigenomic research. Their pioneering work aims to identify epigenetic changes to develop tailored and effective cancer treatments.
Epigenomics explores how our genetics interact with the environment, shaping the molecular codes that influence gene expression patterns. This concept plays a crucial role in oncology as it can help unravel the intricate molecular modifications that influence gene expression patterns and provide valuable insights into cancer development, progression, and potential therapeutic targets.
Join this conversation as Dr. Tost and Prof. Hirst shed light on the remarkable advancements in epigenomics and gain a deeper understanding of the cutting-edge research shaping the future of cancer treatment.
Dr. Jorg Tost, Head of the Laboratory for Epigenetics & Environment at CEA – IBFJ, and Prof. Martin Hirst, Professor and Director of Michael Smith Laboratories at The University of British Columbia share insights into epigenomics research